This may include adverts from us and 3 rd parties based on our understanding. The Integrated Cognitive Assessment ICA test analyses responses to an array of audiovisual cues to screen for early signs of dementia. Developed by the UK health firm Cognetivity Neurosciences, the test has been approved by the US Food and Drug Administration FDA this week for the US markets. According to Cognetivity, the test boasts a high sensitivity to early-stage cognitive impairment, which includes trouble with memory, concentration and learning.
These are the most common early symptoms of dementia, according to the NHS, and are often accompanied by mood swings, confusion and trouble performing everyday tasks. Dr Sina Habibi, Cognetivity's CEO, said: We're delighted to have reached this major company milestone, which is the culmination of many years of hard work. This grants us access to the world's largest healthcare market, where, sadly, there is much more to be done to tackle the massive problem of dementia. Of course, we're excited about the opportunity to revolutionize the way cognitive impairment is assessed and managed in the US and make a positive impact on the health and wellbeing of millions of Americans. Scientists probe 'fifth force of nature' with exciting CERN discovery The ICA has already been approved in Europe and has been rolled out across the UK as a CE-marked medical device. The test is being used by the NHS in both primary and specialist clinical care. It is estimated that more than 850,000 people in the UK have dementia. One in 14 people over 65 are affected by the disease and by 2025, the number of people with dementia is expected to hit one million. And although there is no known cure for dementia, early diagnosis can slow the disease from progressing in some cases.
The NHS said: A diagnosis helps people with dementia get the right treatment and support. It can also help them, and the people close to them, prepare for the future. In the US, more than 2.75 trillion $3.8 trillion was spent on healthcare services in 2018 and the figures are expected to double by 2028. Alzheimer's and other forms of dementia account for a significant chunk of the figure, costing the US some 257 billion $335 billion so far this year. Best supplements for brain health: Enhance working memory EXPLAINED Dementia warning: Popular vitamin that increases Alzheimer's risk INSIGHT Dementia: The warm drink that reduces your risk of mental decline REPORT The figures are expected to grow to 800 billion $1.1 trillion by 2050, and there is a growing demand for early diagnosis. The FDA is the global exemplar of medical regulation; its name carries great weight all over the world. Without a doubt, this mark of certification will bolster our regulatory and commercial efforts in other international jurisdictions as we continue to pursue our ambitions for deployment on a truly global scale.